<!DOCTYPE html>
<html lang="en">
<head>
<!-- Standard favicons -->
<link rel="icon" type="image/x-icon" href="icon/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="icon/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="icon/favicon-32x32.png">

<!-- Apple Touch Icon -->
<link rel="apple-touch-icon" sizes="180x180" href="icon/apple-touch-icon.png">

<!-- Android / Chrome icons -->
<link rel="icon" type="image/png" sizes="192x192" href="icon/android-chrome-192x192.png">
<link rel="icon" type="image/png" sizes="512x512" href="icon/android-chrome-512x512.png">

<!-- Web App Manifest -->
<link rel="manifest" href="icon/site.webmanifest">

<!-- Optional meta tags for theme color and mobile -->
<meta name="theme-color" content="#252526">
<meta name="msapplication-TileColor" content="#252526">
<meta name="msapplication-TileImage" content="icon/favicon-32x32.png">

  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Hyperacusis Guide - Medications & Botox</title>
  <link rel="stylesheet" href="styles.css">
  <link rel="stylesheet" href="styles.css">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.0/css/all.min.css">
</head>
<body>
  <header>
    <h1 class="logo">
    <img src="logo.png" class="logo-image">
    Hyperacusis Guide</h1>
    <button id="hamburger"><?xml version="1.0" encoding="utf-8"?><!-- Uploaded to: SVG Repo, www.svgrepo.com, Generator: SVG Repo Mixer Tools -->
<svg width="40px" height="40px" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg">
<path d="M20 7L4 7" stroke="#e0e0e0" stroke-width="1.5" stroke-linecap="round"/>
<path d="M20 12L4 12" stroke="#e0e0e0" stroke-width="1.5" stroke-linecap="round"/>
<path d="M20 17L4 17" stroke="#e0e0e0" stroke-width="1.5" stroke-linecap="round"/>
</svg></button>
  </header>

  <nav id="sidebar">
    <ul>
      <li><a href="index.html">Precautionary Guide</a></li>
      <li><a href="tinnitus.html">Tinnitus</a></li>
      <li><a href="hyperacusis.html">Hyperacusis</a></li>
      <li><a href="mem.html">MEM & TTTS</a></li>
      <li><a href="imaging.html">Diagnostic Imaging</a></li>
      <li><a href="medications.html">Medications & Botox</a></li>
      <li><a href="silverstein.html">Silverstein Procedure</a></li>
      <li><a href="patch.html">Paper Patching</a></li>
      <li><a href="community.html">Community & Resources</a></li> 
      <li><a href="about.html">About</a></li>
      <li><a href="contact.html">Contact</a></li> 
    </ul>
  </nav>

  <main>
    <article>
      <h1>Medications</h1>

  <p class="lead">
    Various medications have been explored for the management of hyperacusis, noxacusis, and tonic tensor tympani syndrome (TTTS), though none have demonstrated consistent benefits. 
    </p>
    <p>Some patients report temporary relief with benzodiazepines, such as clonazepam or diazepam, which can help calm neural hyperexcitability and reduce anxiety associated with sound sensitivity. 
    However, due to their <strong>high potential for dependence and withdrawal</strong>, benzodiazepines should generally be avoided, with limited use reserved for specific circumstances such as travel.
  </p>
  <p>
    Other medications, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), and anticonvulsants have been tried with variable results.
    </p>
    <p>
       Ambroxol, a mucolytic drug with sodium channel–blocking and neuroprotective properties, has been reported 
        by some patients to reduce pain symptoms in noxacusis, but the results are inconsistent. 
    </p>
    <p>
    Overall, pharmacologic approaches remain largely experimental, and treatment must be individualized and combined with a controlled sound environment to prevent further auditory injury.
    </p>
    <p>
    Real-world data collected from patients who have tried a various treatments including antidepressants, ambroxol, Botox, and tympanic membrane paper patching can be found in the following spreadsheet ─

    <a class="link" href="https://docs.google.com/spreadsheets/d/1-ePvJPk4BhBeoOBKPc1gmXriXd4TYD7Z8n3yyEMoy5I/edit?usp=sharing" target="_blank" rel="noopener noreferrer">Medication, Botox, and Paper Patching Spreadsheet</a>


  </p>

  <h2>
  Summary of medications
  </h2>

  <ul>
    <li><strong>Benzodiazepines (clonazepam, diazepam):</strong> May temporarily reduce sound sensitivity, muscle spasms, and anxiety but carry an extremely high risk of dependence and withdrawal. <i><uL>Withdrawal from benzodiazepines can be extremely difficult, often requiring a gradual taper over many months. In some cases, individuals experience protracted withdrawals that may persist for years, underscoring the need for great caution when using or discontinuing these medications.</ul></i></li>
    <li><strong>Tricyclic antidepressants (clomipramine, amitriptyline, nortriptyline):</strong> Clomipramine has become the most widely used medication for managing hyperacusis and noxacusis symptoms, and while it seems to be highly effective for some, many patients see minimal or no relief from their symptoms.</li>
    <li><strong>SNRIs (duloxetine):</strong> Explored for central pain modulation, variable effectiveness.</li>
    <li><strong>Anticonvulsants (gabapentin, pregabalin):</strong> May help neuropathic auditory pain, variable effectiveness.</li>
    <li><strong>Ambroxol:</strong> Experimental use for neuroprotection and auditory pain relief, variable effectiveness. Ambroxol is generally considered safe and the most common side effects are gastrointentestinal issues and dryness of the mouth and throat.</li>
  </ul>

    <h2>
  Clomipramine
  </h2>

  <p>
  Clomipramine warrants special mention as it has been the most widely used medication for managing hyperacusis and noxacusis symptoms. Among the various pharmacologic options explored, clomipramine has shown the most consistent anecdotal benefit in reducing auditory hypersensitivity and related anxiety.
  </p>
  <p>
  Despite reports of success from many patients, a significant number experienced little to no improvement in their symptoms while using clomipramine. At <i>Hyperacusis Guide</i>, we have reviewed hundreds of patient cases and believe we have identified a specific subgroup that responds most favorably to clomipramine. These patients typically share the following characteristics:
  </p>
  <ul>
      <li><strong>Hyperacusis symptoms are mild:</strong> Patients are able to carry out normal daily activities, continue working, and tolerate normal environmental sounds without fear of a permanent setback, even if this requires the use of hearing protection.<i><ul>Based on our knowledge, no patients who are truly catastrophic and homebound have reported meaningful improvement in their symptoms after taking clomipramine.</ul></i></li>
      <li><strong>No permanent setbacks:</strong> Patients may have a temporary setback from exposing to sound above their tolerance threshold, but return to their previous baseline after a period of rest.</li>
    <li><strong>Neuralgia-type pain:</strong> Almost all of these patients complain of neuralgia-type pain, frequently a burning sensation that radiates from around the ear into the face and head. </li>

  </ul>
  <p>
  Clomipramine belongs to an older class of antidepressants known as tricyclic antidepressants (TCAs). Although effective for certain conditions, TCAs affect multiple neurotransmitter systems and are associated with a wide range of side effects. Clomipramine has additionally been reported to worsen symptoms of <a class="link" href="https://en.wikipedia.org/wiki/Visual_snow_syndrome" target="_blank" rel="noopener noreferrer">visual snow syndrome (VSS)</a>, potentially intensifying visual disturbances like static-like visual noise, light sensitivity, and after-images in susceptible individuals.
  </p>
  <p>
  Several individuals have reported an <strong>initial increase in tinnitus after starting clomipramine</strong>. In many cases, this exacerbation was temporary, with tinnitus gradually returning to baseline after a few weeks of continued use. However, some patients were unable to tolerate the medication and discontinued treatment due to a sustained worsening of tinnitus. Although clomipramine is typically introduced at a low dose, it often must be titrated to doses exceeding 200 mg per day before any meaningful improvement in hyperacusis or noxacusis symptoms is observed, which increases the likelihood of adverse effects.
  </p>
  <p>
  Please refer to the <a class="link" href="https://docs.google.com/spreadsheets/d/1-ePvJPk4BhBeoOBKPc1gmXriXd4TYD7Z8n3yyEMoy5I/edit?usp=sharing" target="_blank" rel="noopener noreferrer">spreadsheet</a>, which provides detailed patient reports on clomipramine use, including information on dosage, effectiveness, and side effects.
  </p>
      <div class="page-break" aria-hidden="true"></div>
      <h1>Botox</h1>

      <p>
        Botox (botulinum toxin type A) has been explored as a potential treatment for hyperacusis, middle ear myoclonus (MEM), 
        and tonic tensor tympani syndrome (TTTS) due to its ability to temporarily weaken overactive muscles involved in 
        abnormal sound perception or middle ear movement. 
      </p>
      <p>
        In cases of MEM or TTTS ─ conditions characterized by involuntary 
        contractions of the tensor tympani or stapedius muscles ─ botox injections have been used to reduce muscle hyperactivity 
        and relieve the associated fluttering, thumping, or pressure sensations in the ear. 
        
        </p>
        <p>
        The toxin is most commonly injected into the tensor veli palatini (TVP) muscle which is closely related to the tensor tympani muscle through a shared tendinous attachement.
        In rare cases, the toxin is directly injected into the tensor tympani and stapedius muscles using a transcanal approach (through the tympanic membrane) under microscopic guidance.
      </p>

       <p>
        The video below demonstrates Botox being injected into the tensor veli palatini (TVP) using a transnasal endoscopic approach. You will notice the tip of the needle tip within the TVP muscle near the lower-left edge of the field of view. <a class="link" href="documents/tvp_botox_letter.pdf" target="_blank" rel="noopener noreferrer">A brief description of the technique can be found 
here</a>. 
      </p>

      <video width="640" height="360" controls poster="video/poster.png">
  <source src="video/tvp_botox.mp4" type="video/mp4">
  Your browser does not support the video tag.
</video>
      <p>
        In some reported cases, patients have experienced a significant reduction in middle ear spasms, sound sensitivity, 
        and pain following treatment, often lasting several months until the effects wear off.
      </p>

      <p>
        For hyperacusis, botox has also been used experimentally to dampen the acoustic reflex or decrease neural overactivity 
        contributing to loudness intolerance. While these findings are promising, evidence remains limited to small case reports 
        and pilot studies, and outcomes vary widely depending on injection technique and the underlying cause of the patient’s 
        symptoms. 
      </p>
      <p>
        Botox treatment for hyperacusis and MEM/TTTS is therefore considered experimental, but may represent a 
        valuable option for patients with refractory symptoms not responsive to medication or sound therapy.
      </p>

    </article>
  </main>
  
  <script src="script.js"></script>
</body>
</html>
